Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025Business Wire • 09/24/25
Positive Phase III Results Show Genentech's Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast CancerBusiness Wire • 09/22/25
Positive phase III results show Roche's giredestrant significantly improved progression-free survival in ER-positive advanced breast cancerGlobeNewsWire • 09/22/25
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNBBusiness Wire • 09/19/25
CHMP recommends EU approval of Roche's subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphomaGlobeNewsWire • 09/19/25
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to PipelineZacks Investment Research • 09/18/25
Roche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total testPRNewsWire • 09/18/25
Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio BuyoutInvestors Business Daily • 09/18/25
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASHGlobeNewsWire • 09/18/25
Roche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experiencePRNewsWire • 09/16/25
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina CongressZacks Investment Research • 09/05/25
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patientsPRNewsWire • 09/05/25
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)GlobeNewsWire • 09/05/25
New Data for Genentech's Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)Business Wire • 09/05/25
Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)GlobeNewsWire • 09/04/25